Novita Pharmaceuticals Announces Oral Presentation of Phase 2 NP-G2-044 Data at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting

NEW YORK, April 23, 2025 /PRNewswire/ -- Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today announced that additional data from its Phase 2...